'Antineoplastons'
- 3 June 1992
- journal article
- research article
- Published by American Medical Association (AMA)
- Vol. 267 (21) , 2924-2928
- https://doi.org/10.1001/jama.1992.03480210086037
Abstract
UNORTHODOX and unproven treatments for cancer are big business in the United States.1,2Usually, individuals providing these treatments offer the public little or no information on their qualifications to treat cancer. Their science is generally presented in unverifiable testimonials, anecdotal material, and non-peer-reviewed magazines sold in supermarkets or publicized on television talk shows and in throwaway health-fair circulars. When reviewed, they reveal a patchwork of half-truths and scientific misinformation. In contrast, there is no lack of published material for the patient who may be considering antineoplaston therapy. There are hundreds of papers about this therapy and its discoverer, Stanislaw R. Burzynski, MD.3-9They include his curriculum vitae, his list of publications, explanations of his theory of cancer and the way his treatment works, clinical information, press releases, brochures, abstracts of his speeches, reports of his research results, review articles, government reports, court opinions, legal depositions, records of publicKeywords
This publication has 2 references indexed in Scilit:
- Inhibitory effect of antineoplaston A-10 on breast cancer transplanted to athymic mice and human hepatocellular carcinoma cell lines.The Kurume Medical Journal, 1990
- Bound amino acids in serum of patients with chronic renal insufficiencyClinica Chimica Acta; International Journal of Clinical Chemistry, 1969